ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced its Swedish partner, Clinical Laserthermia Systems (CLS), has received 510(k) clearance for its laser which the Company plans to commercialize as the ClearPoint Prism™ Neuro Laser Therapy System.
Related news for (CLPT)
- A RUM and AI, Please
- Dawn of Disruption: Ad Tech M&A Frenzy and Venue Visions Light Up Tuesday’s Tape
- clearpoint neuro to announce third quarter 2024 results november 7, 2024
- clearpoint neuro announces early repayment of $10 million note
- ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo